140 related articles for article (PubMed ID: 36004622)
41. Calcineurin Inhibitors Replacement by Ruxolitinib as Graft-versus-Host Disease Prophylaxis for Patients after Allogeneic Stem Cell Transplantation.
Zhao Y; Shi J; Luo Y; Gao F; Tan Y; Lai X; Yu J; Wei G; Huang H
Biol Blood Marrow Transplant; 2020 May; 26(5):e128-e133. PubMed ID: 31982545
[TBL] [Abstract][Full Text] [Related]
42. Skin ulcers caused by ruxolitinib in a patient with chronic cutaneous graft-versus-host disease.
Aslan Candır B; Yiğenoğlu TN; Kızıl Çakar M; Dal MS; Altuntaş F
J Oncol Pharm Pract; 2022 Jun; 28(4):983-985. PubMed ID: 35019785
[TBL] [Abstract][Full Text] [Related]
43. Long-term extracorporeal photochemotherapy in a pediatric patient with refractory sclerodermatous chronic graft-versus-host disease.
Bisaccia E; Palangio M; Gonzalez J
Transfus Apher Sci; 2011 Oct; 45(2):187-90. PubMed ID: 21890415
[TBL] [Abstract][Full Text] [Related]
44. Secondary skin neoplasms in patients after autologous and allogeneic hematopoietic stem cell transplantation procedures.
Szlauer-Stefańska A; Kamińska-Winciorek G; Giebel S; Bagłaj M
Adv Clin Exp Med; 2020 Oct; 29(10):1221-1230. PubMed ID: 33064381
[TBL] [Abstract][Full Text] [Related]
45. [The clinical characteristics of polyserositis as main presentation of chronic graft-versus-host rejection disease after allogeneic hematopoietic stem cell transplantation].
Wang Q; Li Y; Qiu Z; Xu W; Sun Y; Wang L; Wang M; Liu W; Dong Y; Ou J; Wang W; Liang Z; Wang Q; Cen X; Ren H
Zhonghua Nei Ke Za Zhi; 2014 May; 53(5):394-7. PubMed ID: 25146408
[TBL] [Abstract][Full Text] [Related]
46. Sirolimus as part of immunosuppressive therapy for refractory chronic graft-versus-host disease.
Jurado M; Vallejo C; Pérez-Simón JA; Brunet S; Ferra C; Balsalobre P; Pérez-Oteyza J; Espigado I; Romero A; Caballero D; Sierra J; Ribera JM; Díez JL
Biol Blood Marrow Transplant; 2007 Jun; 13(6):701-6. PubMed ID: 17531780
[TBL] [Abstract][Full Text] [Related]
47. Clinical utility of rituximab in chronic graft-versus-host disease.
Bates JS; Engemann AM; Hammond JM
Ann Pharmacother; 2009 Feb; 43(2):316-21. PubMed ID: 19193571
[TBL] [Abstract][Full Text] [Related]
48. Long-Term Follow-Up of Ruxolitinib in the Treatment of Steroid-Refractory Chronic Graft-versus-Host Disease.
Ferreira AM; Szor RS; Molla VC; Seiwald MC; de Moraes PA; da Fonseca ARBM; Xavier EM; Serpa MG; Tucunduva L; Novis Y; Arrais-Rodrigues C
Transplant Cell Ther; 2021 Sep; 27(9):777.e1-777.e6. PubMed ID: 34118469
[TBL] [Abstract][Full Text] [Related]
49. Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study.
Escamilla Gómez V; García-Gutiérrez V; López Corral L; García Cadenas I; Pérez Martínez A; Márquez Malaver FJ; Caballero-Velázquez T; González Sierra PA; Viguria Alegría MC; Parra Salinas IM; Calderón Cabrera C; González Vicent M; Rodríguez Torres N; Parody Porras R; Ferra Coll C; Orti G; Valcárcel Ferreiras D; De la Cámara LLanzá R; Molés P; Velázquez-Kennedy K; João Mende M; Caballero Barrigón D; Pérez E; Martino Bofarull R; Saavedra Gerosa S; Sierra J; Poch M; Zudaire Ripa MT; Díaz Pérez MA; Molina Angulo B; Sánchez Ortega I; Sanz Caballer J; Montoro Gómez J; Espigado Tocino I; Pérez-Simón JA;
Bone Marrow Transplant; 2020 Mar; 55(3):641-648. PubMed ID: 31700138
[TBL] [Abstract][Full Text] [Related]
50. Belumosudil for chronic graft-versus-host disease.
Taylor B; Cohen J; Tejeda J; Wang TP
Drugs Today (Barc); 2022 May; 58(5):203-212. PubMed ID: 35535812
[TBL] [Abstract][Full Text] [Related]
51. Evolving Therapeutic Options for Chronic Graft-versus-Host Disease.
Gonzalez RM; Pidala J
Pharmacotherapy; 2020 Aug; 40(8):756-772. PubMed ID: 32441379
[TBL] [Abstract][Full Text] [Related]
52. Ruxolitinib is an effective salvage treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation without posttransplant cyclophosphamide.
Zhao JY; Liu SN; Xu LP; Zhang XH; Wang Y; Chen YH; Liu KY; Huang XJ; Mo XD
Ann Hematol; 2021 Jan; 100(1):169-180. PubMed ID: 33159239
[TBL] [Abstract][Full Text] [Related]
53. Ruxolitinib-corticosteroid as first-line therapy for newly diagnosed high-risk acute graft versus host disease: study protocol for a multicenter, randomized, phase II controlled trial.
Dou L; Peng B; Li X; Wang L; Jia M; Xu L; Li F; Liu D
Trials; 2022 Jun; 23(1):470. PubMed ID: 35668528
[TBL] [Abstract][Full Text] [Related]
54. Safety analysis of patients who received ruxolitinib for steroid-refractory acute or chronic graft-versus-host disease in an expanded access program.
Schroeder MA; Hari PN; Blithe A; Paranagama D; Bhatt V; DiPersio JF
Bone Marrow Transplant; 2022 Jun; 57(6):975-981. PubMed ID: 35437311
[TBL] [Abstract][Full Text] [Related]
55. Janus Kinase Inhibition for Graft-Versus-Host Disease: Current Status and Future Prospects.
Mannina D; Kröger N
Drugs; 2019 Sep; 79(14):1499-1509. PubMed ID: 31359326
[TBL] [Abstract][Full Text] [Related]
56. Eczematoid graft-vs-host disease: a novel form of chronic cutaneous graft-vs-host disease and its response to psoralen UV-A therapy.
Creamer D; Martyn-Simmons CL; Osborne G; Kenyon M; Salisbury JR; Devereux S; Pagliuca A; Ho AY; Mufti GJ; du Vivier AW
Arch Dermatol; 2007 Sep; 143(9):1157-62. PubMed ID: 17875877
[TBL] [Abstract][Full Text] [Related]
57. Treatment of cutaneous and/or soft tissue manifestations of corticosteroids refractory chronic graft versus host disease (cGVHD) by a total nodal irradiation (TNI).
Peyraga G; Lizee T; Gustin P; Clement-Colmou K; Di Bartolo C; Supiot S; Mahe MA; François S; Mege M
Clin Transplant; 2017 Apr; 31(4):. PubMed ID: 28181304
[TBL] [Abstract][Full Text] [Related]
58. Changes in Immunosuppressive Treatment of Chronic Graft-versus-Host Disease: Comparison of 2 Surveys within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland.
Wolff D; Hilgendorf I; Wagner-Drouet E; Jedlickova Z; Ayuk F; Zeiser R; Schäfer-Eckart K; Gerbitz A; Stadler M; Klein S; Middeke JM; Lawitschka A; Winkler J; Halter J; Holler E; Kobbe G; Stelljes M; Ditschkowski M; Greinix H
Biol Blood Marrow Transplant; 2019 Jul; 25(7):1450-1455. PubMed ID: 30876928
[TBL] [Abstract][Full Text] [Related]
59. Alemtuzumab-induced resolution of refractory cutaneous chronic graft-versus-host disease.
Ruiz-Argüelles GJ; Gil-Beristain J; Magaña M; Ruiz-Delgado GJ
Biol Blood Marrow Transplant; 2008 Jan; 14(1):7-9. PubMed ID: 18158955
[TBL] [Abstract][Full Text] [Related]
60. Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era?
Lestang E; Peterlin P; Le Bris Y; Dubruille V; Delaunay J; Godon C; Theisen O; Blin N; Mahe B; Gastinne T; Garnier A; Touzeau C; Voldoire M; Bene MC; Le Gouill S; Milpied N; Mohty M; Moreau P; Guillaume T; Chevallier P
Eur J Haematol; 2017 Jul; 99(1):60-69. PubMed ID: 28370306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
